Connection

WOLFGANG WINKELMAYER to Clinical Trials as Topic

This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Clinical Trials as Topic.
  1. Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. Nephrol Dial Transplant. 2020 10 01; 35(10):1761-1769.
    View in: PubMed
    Score: 0.130
  2. Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. Am J Kidney Dis. 2020 07; 76(1):109-120.
    View in: PubMed
    Score: 0.127
  3. Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017 08; 92(2):297-305.
    View in: PubMed
    Score: 0.104
  4. Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. Am J Kidney Dis. 2017 Oct; 70(4):464-475.
    View in: PubMed
    Score: 0.101
  5. Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. Trials. 2015 Aug 19; 16:364.
    View in: PubMed
    Score: 0.091
  6. Surrogate markers in clinical studies: problems solved or created? Am J Kidney Dis. 2006 Jul; 48(1):159-66.
    View in: PubMed
    Score: 0.048
  7. Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease. Expert Opin Investig Drugs. 2000 Nov; 9(11):2637-51.
    View in: PubMed
    Score: 0.033
  8. Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019 05; 95(5):1027-1036.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.